Sugi Predict

Sugi Predict / Compounds / SCHEMBL17555652

SCHEMBL17555652

SCHEMBL17555652

CN1CCN(c2ccnc(N)c2[N+](=O)[O-])CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.46
▸ GPR55 Q9Y2T6 1/20 0.46
▸ RPS6KB1 P23443 1/20 0.46
▸ SIRT6 Q8N6T7 2/20 0.45
▸ HPGD P15428 1/20 0.44
▸ HRH4 Q9H3N8 2/20 0.43
▸ HRH3 Q9Y5N1 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ HTT P42858 4/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ LMNA P02545 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ WDR5 P61964 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ S100A4 P26447 1/20 0.41
▸ MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4467502 0.79 ALDH1A1 (0.56) MAPTALDH1A1LMNA
SCHEMBL17555900 0.77 MAPT (0.49) MAPTGPR55RPS6KB1SIRT6HPGD
SCHEMBL3037851 0.77 HRH4 (0.51) MAPTHRH4HRH3L3MBTL1HTT
SCHEMBL949823 0.77 DHFR (0.52) MAPTL3MBTL1HTTSMN1; SMN2ALDH1A1
SCHEMBL12517567 0.77 ALDH1A1 (0.52) MAPTHPGDL3MBTL1HTTSMN1; SMN2
SCHEMBL1509487 0.77 ADRA2C (0.58) MAPTGPR55SIRT6HRH4L3MBTL1
SCHEMBL4884796 0.74 MAPT (0.50) MAPTSIRT6SMN1; SMN2ALDH1A1LMNA
SCHEMBL28845817 0.74 WDR5 (0.52) SIRT6HRH4HTTSMN1; SMN2ALDH1A1
SCHEMBL23122993 0.72 ADRA2C (0.53) MAPTGPR55SIRT6L3MBTL1HTT
SCHEMBL29745024 0.72 ADRA2C (0.53) MAPTGPR55SIRT6L3MBTL1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10329309-B2 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof SAMUMED, LLC (US) 2019-06-25 — — US disclosed
US-10280166-B2 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2019-05-07 — — US disclosed
US-10280166-B2 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2019-05-07 — — US disclosed
US-20190119303-A1 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2019-04-25 — — US disclosed
US-20190055238-A1 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2019-02-21 — — US disclosed
US-20190055238-A1 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2019-02-21 — — US disclosed
US-10131677-B2 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2018-11-20 — — US disclosed
US-20180222923-A1 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B] PYRIDINES AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2018-08-09 — — US disclosed
US-20180222923-A1 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B] PYRIDINES AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2018-08-09 — — US disclosed
US-20180201624-A1 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2018-07-19 — — US disclosed
US-20160090380-A1 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF MED-PATHWAYS II LIMITED (VG) 2016-03-31 — — US disclosed
WO-2016040184-A1 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF SAMUMED, LLC (US) 2016-03-17 — — WO disclosed
WO-2016040190-A1 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF SAMUMED, LLC (US) 2016-03-17 — — WO disclosed
WO-2016040185-A1 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF SAMUMED, LLC (US) 2016-03-17 — — WO disclosed
US-20160068550-A1 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2016-03-10 — — US disclosed
US-20160068551-A1 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2016-03-10 — — US disclosed
US-20160068550-A1 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2016-03-10 — — US disclosed
US-20160068550-A1 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2016-03-10 — — US disclosed
CN-102675305-B Imidazopyridine compounds, as well as preparation method and application thereof SHANGHAI INST MATERIA MEDICA 2014-11-12 — — CN disclosed
CN-103570683-A Multi-substituted amine compound, as well as preparation method and use thereof SHANGHAI INST MATERIA MEDICA 2014-02-12 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119303-A1 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A MAPT 3343/4885GPR55 1800/4885RPS6KB1 610/4885
US-20160068550-A1 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A MAPT 3343/4885GPR55 1800/4885RPS6KB1 610/4885
US-10329309-B2 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof WNT1, WNT3, WNT3A MAPT 2691/4885GPR55 2583/4885RPS6KB1 907/4885
US-20180201624-A1 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF WNT3, WNT1, WNT3A MAPT 3399/4885GPR55 1781/4885RPS6KB1 840/4885
US-10280166-B2 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof WNT1, WNT3, WNT3A MAPT 2120/4885GPR55 1947/4885RPS6KB1 679/4885
US-20160068551-A1 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF WNT3, WNT1, WNT3A MAPT 3399/4885GPR55 1781/4885RPS6KB1 840/4885
US-10131677-B2 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof WNT1, WNT3, WNT3A MAPT 3343/4885GPR55 1800/4885RPS6KB1 610/4885
US-20190055238-A1 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A MAPT 2120/4885GPR55 1947/4885RPS6KB1 679/4885
US-20160090380-A1 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A MAPT 2120/4885GPR55 1947/4885RPS6KB1 679/4885
US-20180222923-A1 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B] PYRIDINES AND THERAPEUTIC USES THEREOF WNT1, WNT3A, WNT3 MAPT 3198/4885GPR55 1994/4885RPS6KB1 621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.